AMAG Pharmaceuticals Inc. (AMAG)

21.27
0.48 2.20
NASDAQ : Health Technology
Prev Close 21.75
Open 20.65
Day Low/High 19.50 / 21.75
52 Wk Low/High 11.93 / 25.62
Volume 1.72M
Avg Volume 777.10K
Exchange NASDAQ
Shares Outstanding 34.33M
Market Cap 725.16M
EPS -5.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AMAG Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of AMAG Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $20.55, changing hands for $20.70/share.

First Week Of June 15th Options Trading For AMAG Pharmaceuticals (AMAG)

Investors in AMAG Pharmaceuticals, Inc. saw new options begin trading this week, for the June 15th expiration.

AMAG Will Make You Think Biotech Again

AMAG Will Make You Think Biotech Again

When this stock hit my breakout scan, I paid it a bit of extra attention.

AMAG Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of AMAG Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $20.80, changing hands for $21.00/share.

First Week Of AMAG November 16th Options Trading

First Week Of AMAG November 16th Options Trading

Investors in AMAG Pharmaceuticals, Inc. saw new options begin trading this week, for the November 16th expiration.

Palatin Technologies Announces Submission Of Bremelanotide NDA To FDA For Treatment Of Hypoactive Sexual Desire Disorder (HSDD) In Premenopausal Women

Palatin Technologies Announces Submission Of Bremelanotide NDA To FDA For Treatment Of Hypoactive Sexual Desire Disorder (HSDD) In Premenopausal Women

NDA includes data from two successful Phase 3 trials in HSDD in premenopausal women in which bremelanotide met the pre-specified co-primary efficacy endpoints

First Week of April 20th Options Trading For AMAG Pharmaceuticals (AMAG)

First Week of April 20th Options Trading For AMAG Pharmaceuticals (AMAG)

Investors in AMAG Pharmaceuticals, Inc. saw new options become available this week, for the April 20th expiration.

AMAG Pharmaceuticals Announces FDA Approval Of Makena® (hydroxyprogesterone Caproate Injection) Subcutaneous Auto-Injector To Reduce The Risk Of Preterm Birth In Certain At-Risk Women

AMAG Pharmaceuticals Announces FDA Approval Of Makena® (hydroxyprogesterone Caproate Injection) Subcutaneous Auto-Injector To Reduce The Risk Of Preterm Birth In Certain At-Risk Women

Marks Second FDA Approval for AMAG this Month; Company to File NDA for Bremelanotide, A Novel Women's Health Product, Later this Quarter

AMAG Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application (sNDA) For Feraheme® (ferumoxytol Injection)

AMAG Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application (sNDA) For Feraheme® (ferumoxytol Injection)

Feraheme is Now a Treatment Option for All Eligible Adult Patients with Iron Deficiency Anemia

Noteworthy Monday Option Activity: AMAG, ACIA, HCA

Noteworthy Monday Option Activity: AMAG, ACIA, HCA

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AMAG Pharmaceuticals, Inc. , where a total volume of 4,588 contracts has been traded thus far today, a contract volume which is representative of approximately 458,800 underlying shares (given that every 1 contract represents 100 underlying shares).

New Patent Issued To AMAG Pharmaceuticals Entitled "Methods Of Reducing Risk Of Preterm Birth"

New Patent Issued To AMAG Pharmaceuticals Entitled "Methods Of Reducing Risk Of Preterm Birth"

Patent designed to protect the subcutaneous administration of Makena(R) (hydroxyprogesterone caproate injection)

AMAG Announces Autologous Cord Blood Cells Improve Motor Function In Some Children With Cerebral Palsy

AMAG Announces Autologous Cord Blood Cells Improve Motor Function In Some Children With Cerebral Palsy

More than one-third of study participants in Phase 2 Study were Cord Blood Registry® (CBR®) clients

AMAG Pharmaceuticals Enters Oversold Territory (AMAG)

AMAG Pharmaceuticals Enters Oversold Territory (AMAG)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Purchase AMAG Pharmaceuticals At $12, Earn 13.2% Annualized Using Options

Commit To Purchase AMAG Pharmaceuticals At $12, Earn 13.2% Annualized Using Options

Investors eyeing a purchase of AMAG Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $17.50/share, might benefit from considering selling puts among the alternative strategies at their disposal.

TheStreet Quant Rating: D+ (Sell)